ANTHONY S CHICKEN NECK FAUCI PATENTS.

 

Patents by Inventor Anthony S. Fauci

Anthony S. Fauci has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

• Use of antagonists of the interaction between HIV GP120 and ?4?7 integrin

  Patent number: 9896509

  Abstract: Methods are provided for the treatment of a HIV infection. The methods can include administering to a subject with an HIV infection a therapeutically effective amount of an agent that interferes with the interaction of gp120 and ?4 integrin, such as a ?4?1 or ?4?7 integrin antagonist, thereby treating the HIV infection. In several examples, the ?4 integrin antagonist is a monoclonal antibody that specifically binds to a ?4, ?1 or ?7 integrin subunit or a cyclic hexapeptide with the amino acid sequence of CWLDVC. Methods are also provided to reduce HIV replication or infection. The methods include contacting a cell with an effective amount of an agent that interferes with the interaction of gp120 and ?4 integrin, such as a ?4?1 or ?4?7 integrin antagonist. Moreover, methods are provided for determining if an agent is useful to treat HIV.

  Type: Grant

  Filed: August 3, 2016

  Date of Patent: February 20, 2018

  Assignee: The United States of America, as Represented by the Secretary, Department of Health and Human Services

  Inventors: James Arthos, Diana Goode, Claudia Cicala, Anthony S. Fauci

• USE OF ANTAGONISTS OF THE INTERACTION BETWEEN HIV GP120 AND A4B7 INTEGRIN

  Publication number: 20160333097

  Abstract: Methods are provided for the treatment of a HIV infection. The methods can include administering to a subject with an HIV infection a therapeutically effective amount of an agent that interferes with the interaction of gp120 and ?4 integrin, such as a ?4?1 or ?4?7 integrin antagonist, thereby treating the HIV infection. In several examples, the ?4 integrin antagonist is a monoclonal antibody that specifically binds to a ?4, ?1 or ?7 integrin subunit or a cyclic hexapeptide with the amino acid sequence of CWLDVC. Methods are also provided to reduce HIV replication or infection. The methods include contacting a cell with an effective amount of an agent that interferes with the interaction of gp120 and ?4 integrin, such as a ?4?1 or ?4?7 integrin antagonist. Moreover, methods are provided for determining if an agent is useful to treat HIV.

  Type: Application

  Filed: August 3, 2016

  Publication date: November 17, 2016

  Applicant: THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human Serv

  Inventors: James Arthos, Diana Goode, Claudia Cicala, Anthony S. Fauci

• Use of antagonists of the interaction between HIV GP120 and ?4?7 integrin

  Patent number: 9441041

  Abstract: Methods are provided for the treatment of a HIV infection. The methods can include administering to a subject with an HIV infection a therapeutically effective amount of an agent that interferes with the interaction of gp120 and ?4 integrin, such as a ?4?1 or ?4?7 integrin antagonist, thereby treating the HIV infection. In several examples, the ?4 integrin antagonist is a monoclonal antibody that specifically binds to a ?4, ?1 or ?7 integrin subunit or a cyclic hexapeptide with the amino acid sequence of CWLDVC. Methods are also provided to reduce HIV replication or infection. The methods include contacting a cell with an effective amount of an agent that interferes with the interaction of gp120 and ?4 integrin, such as a ?4?1 or ?4?7 integrin antagonist. Moreover, methods are provided for determining if an agent is useful to treat HIV.

  Type: Grant

  Filed: September 21, 2015

  Date of Patent: September 13, 2016

  Assignee: The United States of America, as Represented by the Secretary, Department of Health and Human Services

  Inventors: James Arthos, Diana Goode, Claudia Cicala, Anthony S. Fauci

• USE OF ANTAGONISTS OF THE INTERACTION BETWEEN HIV GP120 AND A4B7 INTEGRIN

  Publication number: 20160075786

  Abstract: Methods are provided for the treatment of a HIV infection. The methods can include administering to a subject with an HIV infection a therapeutically effective amount of an agent that interferes with the interaction of gp120 and ?4 integrin, such as a ?4?1 or ?4?7 integrin antagonist, thereby treating the HIV infection. In several examples, the ?4 integrin antagonist is a monoclonal antibody that specifically binds to a ?4, ?1 or ?7 integrin subunit or a cyclic hexapeptide with the amino acid sequence of CWLDVC. Methods are also provided to reduce HIV replication or infection. The methods include contacting a cell with an effective amount of an agent that interferes with the interaction of gp120 and ?4 integrin, such as a ?4?1 or ?4?7 integrin antagonist. Moreover, methods are provided for determining if an agent is useful to treat HIV.

  Type: Application

  Filed: September 21, 2015

  Publication date: March 17, 2016

  Applicant: The United States of America, as Represented by the Secretary, Department of Health and Human Serv

  Inventors: James Arthos, Diana Goode, Claudia Cicala, Anthony S. Fauci

• IMMUNOCONJUGATES COMPRISING CD4 AND IMMUNOGLOBIN MOLECULES FOR THE TREATMENT OF HIV INFECTION

  Publication number: 20090285815

  Abstract: Nucleic acids encoding recombinant CD4-fusion proteins are disclosed herein that include a CD4 polypeptide ligated at its C-terminus with a portion of an immunoglobulin comprising a hinge region and a constant domain of a mammalian immunoglobulin heavy chain. The portion of the IgG is fused at its C-terminus with a polypeptide comprising a tailpiece from the C terminus of the heavy chain of an IgA antibody or a tailpiece from a C terminus of the heavy chain of an IgM antibody. Also disclosed herein are methods for using these CD4-fusion proteins.

  Type: Application

  Filed: March 21, 2008

  Publication date: November 19, 2009

  Inventors: James Arthos, Claudia Cicala, Anthony S. Fauci

• Fusion protein including of CD4

  Patent number: 7368114

  Abstract: Novel recombinant polypeptides are disclosed herein that include a CD4 polypeptide ligated at its C-terminus with a portion of an immunoglobulin comprising a hinge region and a constant domain of a mammalian immunoglobulin heavy chain. The portion or the IgG is fused at its C-terminus with a polypeptide comprising a tailpiece from the C-terminus of the heavy chain of an IgA antibody ara tailpiece from a C-terminus of the heavy chain of an IgM antibody. Also disclosed herein are methods for using these CD4 fusion proteins.

  Type: Grant

  Filed: October 24, 2002

  Date of Patent: May 6, 2008

  Assignee: The United States of America as represented by the Department of Health and Human Services

  Inventors: James Arthos, Claudia Cicala, Anthony S. Fauci

• HIV related peptides

  Patent number: 6911527

  Abstract: This invention is the discovery of novel specific epitopes and antibodies associated with long term survival of HIV-1 infections. These epitopes and antibodies have use in preparing vaccines for preventing HIV-1 infection or for controlling progression to AIDS.

  Type: Grant

  Filed: January 7, 2000

  Date of Patent: June 28, 2005

  Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services

  Inventors: Giuseppe Scala, Xueni Chen, Oren J. Cohen, Anthony S. Fauci

• Efficient inhibition of hiv-1 viral entry through a novel fusion protein including of cd4

  Publication number: 20040265306

  Abstract: Novel recombinant polypeptides are disclosed herein that include a CD4 polypeptide ligated at its C-terminus with a portion of an immunoglobulin comprising a hinge region and a constant domain of a mammalian immunoglobulin heavy chain. The portion of the IgG is fused at its C-terminus with a polypeptide comprising a tailpiece from the C-terminus of the heavy chain of an IgA antibody or a tailpiece from a C-terminus of the heavy chain of an IgM antibody. Also disclosed herein are methods for using these CD4-fusion proteins.

  Type: Application

  Filed: July 27, 2004

  Publication date: December 30, 2004

  Inventors: James Arthos, Claudia Cicala, Anthony S. Fauci

• Immunologic enhancement with intermittent interleukin-2 therapy

  Publication number: 20030180254

  Abstract: A method for activating a mammalian immune system entails a series of IL-2 administrations that are effected intermittently over an extended period. Each administration of IL-2 is sufficient to allow spontaneous DNA synthesis in peripheral blood or lymph node cells of the patient to increase and peak, and each subsequent administration follows the preceding administration in the series by a period of time that is sufficient to allow IL-2 receptor expression in peripheral or lymph node blood of the patient to increase, peak and then decrease to 50% of peak value. This intermittent IL-2 therapy can be combined with another therapy which targets a specific disease state, such as an anti-retroviral therapy comprising, for example, the administration of AZT, ddI or interferon alpha. In addition, IL-2 administration can be employed to facilitate in situ transduction of T cells in the context of gene therapy.

  Type: Application

  Filed: January 23, 2003

  Publication date: September 25, 2003

  Applicant: The Govt. of the USA as represented by the Secretary of the Dept. of Health & Human Services

  Inventors: H. Clifford Lane, Joseph A. Kovacs, Anthony S. Fauci

• Immunologic enhancement with intermittent interleukin-2 therapy

  Patent number: 6548055

  Abstract: A method for activating a mammalian immune system entails a series of IL-2 administrations that are effected intermittently over an extended period. Each administration of IL-2 is sufficient to allow spontaneous DNA synthesis in peripheral blood or lymph node cells of the patient to increase and peak, and each subsequent administration follows the preceding administration in the series by a period of time that is sufficient to allow IL-2 receptor expression in peripheral or lymph node blood of the patient to increase, peak and then decrease to 50% of peak value. This intermittent IL-2 therapy can be combined with another therapy which targets a specific disease state, such as an anti-retroviral therapy comprising, for example, the administration of AZT, ddI or interferon alpha. In addition, IL-2 administration can be employed to facilitate in situ transduction of T cells in the context of gene therapy.

  Type: Grant

  Filed: August 9, 2000

  Date of Patent: April 15, 2003

  Assignee: The United States of America as represented by the Department of Health and Human Services

  Inventors: H. Clifford Lane, Joseph A. Kovacs, Anthony S. Fauci

• Immunologic enhancement with intermittent interleukin-2 therapy

  Patent number: 6190656

  Abstract: A method for activating a mammalian immune system entails a series of IL-2 administrations that are effected intermittently over an extended period. Each administration of IL-2 is sufficient to allow spontaneous DNA synthesis in peripheral blood or lymph node cells of the patient to increase and peak, and each subsequent administration follows the preceding administration in the series by a period of time that is sufficient to allow IL-2 receptor expression in peripheral or lymph node blood of the patient to increase, peak and then decrease to 50% of peak value. This intermittent IL-2 therapy can be combined with another therapy which targets a specific disease state, such as an anti-retroviral therapy comprising, for example, the administration of AZT, ddI or interferon alpha. In addition, IL-2 administration can be employed to facilitate in situ transduction of T cells in the context of gene therapy.

  Type: Grant

  Filed: September 2, 1997

  Date of Patent: February 20, 2001

  Assignee: The United States of America as represented by the Department of Health and Human Services

  Inventors: H. Clifford Lane, Joseph A. Kovacs, Anthony S. Fauci

• Immunologic enhancement with intermittent interleukin-2 therapy

  Patent number: 5696079

  Abstract: A method for activating a mammalian immune system entails a series of IL-2 administrations that are effected intermittently over an extended period. Each administration of IL-2 is sufficient to allow spontaneous DNA synthesis in peripheral blood or lymph node cells of the patient to increase and peak, and each subsequent administration follows the preceding administration in the series by a period of time that is sufficient to allow IL-2 receptor expression in peripheral or lymph node blood of the patient to increase, peak and then decrease to 50% of peak value. This intermittent IL-2 therapy can be combined with another therapy which targets a specific disease state, such as an anti-retroviral therapy comprising, for example, the administration of AZT, ddI or interferon alpha. In addition, IL-2 administration can be employed to facilitate in situ transduction of T cells in the context of gene therapy.

  Type: Grant

  Filed: May 26, 1995

  Date of Patent: December 9, 1997

  Assignee: The United States of America as represented by the Department of Health and Human Services

  Inventors: H. Clifford Lane, Joseph A. Kovacs, Anthony S. Fauci